Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia

Rachel Thijssen, Johanna ter Burg, Brett Garrick, Gregor G. W. van Bochove, Jennifer R. Brown, Stacey M. Fernandes, María Solé Rodríguez, Jean-Marie Michot, Michael Hallek, Barbara Eichhorst, Hans Christian Reinhardt, Johanna Bendell, Ingrid A. M. Derks, Roel J. W. van Kampen, Kristen Hege, Marie José Kersten, Torsten Trowe, Ellen H. Filvaroff, Eric Eldering, Arnon P. Kater

Research output: Contribution to journalArticleAcademicpeer-review

62 Citations (Scopus)


Inhibition of B-cell receptor (BCR) signaling pathways in chronic lymphocytic leukemia (CLL) provides significant clinical benefit to patients, mainly by blocking adhesion of CLL cells in the lymph node microenvironment. The currently applied inhibitors ibrutinib and idelalisib have limited capacity however to induce cell death as monotherapy and are unlikely to eradicate the disease. Acquired resistance to therapy in CLL is often caused by mutations in the response network being targeted, both for DNA damage or BCR signaling pathways. Thus, drugs with dual targeting capacity could offer improved therapeutic value. Here, the potency of CC-115, a novel inhibitor of mammalian target of rapamycin kinase (TORK) and DNA-dependent protein kinase (DNA-PK), was evaluated in primary CLL cells in vitro and in CLL patients. Combined TORK and DNA-PK inhibition in vitro resulted in caspase-dependent cell killing irrespective of p53, ATM, NOTCH1, or SF3B1 status. Proliferation induced by CD40(+) interleukin-21 stimulation was completely blocked by CC-115, and CD40-mediated resistance to fludarabine and venetoclax could be reverted by CC-115. BCR-mediated signaling was inhibited by CC-115 and also in CLL samples obtained from patients with acquired resistance to idelalisib treatment. Clinical efficacy of CC-115 was demonstrated in 8 patients with relapsed/refractory CLL/small lymphocytic lymphoma harboring ATM deletions/mutations; all but 1 patient had a decrease in lymphadenopathy, resulting in 1 IWCLL partial response (PR) and 3 PRs with lymphocytosis. In conclusion, these preclinical results, along with early promising clinical activity, suggest that CC-115 may be developed further for treatment of CLL. The trial was registered at www.clinicaltrials.gov as #NCT01353625
Original languageEnglish
Pages (from-to)574-583
Issue number4
Publication statusPublished - 2016

Cite this